NYSE American · Drug Manufacturers - General · USD

Nasus Pharma Ltd. (NSRX) Stock Analysis

Nasus Pharma Ltd. (NSRX) is a Drug Manufacturers - General stock listed on NYSE American and quoted in US Dollar.

NSRX

$3.74

−$0.02 (−0.40%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare NSRX with… →

NSRX Key Statistics

As of Sep 4, 2026

Trading

Open: $3.53
Previous Close: $3.75
Day's Range: 3.53–3.74
52-Week Range: 1.98–9.50
Volume: 800

Valuation

Market Cap: $43.75M
P/E Ratio: unprofitable
EPS (ttm): −1.13

Financials (FY)

Revenue (FY): $0.00
Net Income (FY): −$5.86M
Profit margin: 0.00%
Shares Outstanding: 11.71M
1-Year Return: −53.38%

Dividend and dates

Avg Volume: 18.22K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

NSRX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

Year	Return
2026 (partial year)	−59.18%
2025 (partial year)	+10.91%

As of September 4, 2026.

NSRX Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$0.00	−$5.86M	—
2024	$0.00	−$1.53M	—
2023	$0.00	−$1.05M	—
2022	$0.00	−$1.71M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$0.00	—	−$4.90M	−$5.86M	—
2024	$0.00	—	−$1.08M	−$1.53M	—
2023	$0.00	—	−$1.15M	−$1.05M	—
2022	$0.00	—	−$2.04M	−$1.71M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

NSRX Valuation vs Drug Manufacturers - General Median

Median of 21 stocks

Metric	NSRX	Drug Manufacturers - General median	vs median
Profit margin	0.00%	8.09%	8.1 pts below

Medians across 21 Drug Manufacturers - General stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Nasus Pharma Ltd. (NSRX) at $43.75M. It is classified in the Drug Manufacturers - General industry, within the Healthcare sector. Headcount on file is 7.

Over the past 52 weeks the price has ranged from $1.98 to $9.50. The most recent close on file for NSRX is $3.74, dated September 4, 2026. That is −$0.02 (−0.40%) against the previous close. The latest close sits 88.64% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $5.86M. The reported profit margin is 0%. That is 8.1 percentage points below the Drug Manufacturers - General median of 8.09%. Trailing earnings per share are −1.13.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Annualized volatility over the trailing 1 year is 101.59%. Over the trailing twelve months the price has returned −53.38%.

Growth & Income

The record shows no dividend for NSRX.

So far in 2026 the price is −59.18%.

Peer Comparison

Nasus Pharma Ltd. (NSRX) operates in the Drug Manufacturers - General industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Nasus Pharma Ltd.	NSRX	$43.75M	—
Eli Lilly and Company	LLY	$1.02T	38.6
Johnson & Johnson	JNJ	$663.28B	32.0
AbbVie Inc.	ABBV	$453.19B	73.5

The Drug Manufacturers - General industry average P/E ratio is 24.7x. Nasus Pharma Ltd. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Drug Manufacturers - General Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

NVS

Novartis AG

$304.10B

AZN

AstraZeneca PLC

$252.33B

View all Drug Manufacturers - General stocks →

Popular Healthcare Stocks

UNH

UnitedHealth Group Incorporated

$356.47B

AMGN

Amgen Inc.

$236.38B

TMO

Thermo Fisher Scientific Inc.

$226.94B

NVO

Novo Nordisk A/S

$206.02B

ABT

Abbott Laboratories

$187.45B

View all Healthcare stocks →

About Nasus Pharma Ltd.

Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel.

Visit website →